Latest Breaking News On - Study looking - Page 1 : comparemela.com

NVX-CoV2373 COVID-19 Vaccine Description NVX-CoV2373 is a prefusion protein coronavirus vaccine candidate made using Novavax’s proprietary nanoparticle technology, Matrix-M, an adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies. Novavax’s patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response and helping an immunized person make antibodies against the virus. Novavax identified the recombinant nanoparticle NVX‑CoV2373 vaccine as its lead COVID-19 candidate following pre-clinical testing that demonstrated high immunogenicity and high levels of neutralizing antibodies.

United statesNorth carolinaUnited kingdomSouth africaUniversity of maryland school medicineNew zealandSouth koreaCommonwealth of australiaRepublic of koreaFranciss collinsShabir madhiKaren kotloffGregorym glennStanleyc erckHalle westfalenAnthonys fauci